Cipla's USFDA inspection of its subsidiary's New York facility has been classified as 'Voluntary Action Indicated' (VAI), indicating the regulator has identified issues requiring voluntary corrective action rather than formal regulatory action. According to CNBC TV18, the US Food and Drug Administration inspected Unit 3 of InvaGen Pharmaceuticals at Central Islip in Long Island, New York, from July 13 to July 17, 2026. Cipla disclosed this classification in a regulatory filing dated August 28, 2026. The VAI classification places the inspection in a category where the regulator has identified issues requiring voluntary corrective action, though the company's filing does not disclose specific observations or details of corrective measures. InvaGen Pharmaceuticals Inc., which operates the facility, is a wholly owned subsidiary of Cipla.
The regulatory developments come alongside action by the Maharashtra Food and Drug Administration, which cancelled the drug sale licences of Cipla Pharma & Life Sciences' Carry & Forwarding facility at Wadki in Pune, effective August 27. As reported by CNBC TV18, this action followed an inspection linked to Reactin Plus Tablets, with the regulator citing discrepancies in stock records, storage deficiencies and non-compliance with directions to recall the medicine. The FDA also seized stock worth ₹11.19 lakh from Cipla Pharma & Life Sciences' main warehouse in Wadki in June. Maharashtra FDA Commissioner Tukaram Mundhe emphasized the regulator would not show leniency on issues concerning drug safety and public health, stating legal requirements governing the advertising, sale, storage and distribution of Schedule H medicines must be followed.
Cipla shares declined 1.59% to close at ₹1,415 on Tuesday following the company's disclosure of USFDA inspection findings. According to reports from CNBC TV18, the US Food and Drug Administration conducted a follow-up current Good Manufacturing Practices (cGMP) inspection at Cipla's Pithampur facility from August 17 to August 25, 2026. The company received seven inspectional observations in Form 483 following the conclusion of the inspection. As per CNBC TV18, a Form 483 flags conditions or practices that USFDA inspectors believe may violate regulatory requirements, but it doesn't constitute a final regulatory action against the company or the plant. Cipla stated it will work closely with the USFDA and is committed to addressing the observations 'comprehensively within the stipulated time'.
Despite the regulatory setback, brokerage firm Citi maintained its 'Buy' rating on Cipla with a target price of ₹1,700, implying an upside of around 20.1% from Tuesday's closing price of ₹1,415. According to CNBC TV18, Citi expects the latest USFDA observations to have no impact on near- to medium-term earnings, as key pipeline approvals are linked to the company's Goa and US facilities. The brokerage firm noted that even a further delay in regulatory resolution is unlikely to affect its earnings estimates, given that the Pithampur facility is already under a Warning Letter. However, Citi emphasized that a resolution of the regulatory issues at Pithampur would be a significant positive over the longer term, allowing Cipla to manage supplies of key respiratory products, including generic Symbicort and generic Ventolin, more efficiently.
The regulatory developments come after Cipla reported challenging financial results for the first quarter of FY27. As reported by CNBC TV18, consolidated net profit fell 39% to ₹789 crore in Q1 FY27, compared with ₹1,291.61 crore in the corresponding quarter of the previous fiscal. The company attributed the decline mainly to weaker sales in the North American market and higher expenses. Despite the profit decline, consolidated total revenue from operations increased 2.3% year-on-year to ₹7,119 crore from ₹6,957.5 crore in the year-ago period. However, operating performance was weaker with EBITDA falling 33% to ₹1,192 crore from ₹1,778.1 crore, while the EBITDA margin narrowed to 16.7% from 25.6%. The company's revenue growth was driven by its India, Africa and emerging-markets businesses, partly offset by weakness in North America.
Cipla's shares are currently 15% below their 52-week high of ₹1,673, which was recorded on October 23, 2025. As reported by CNBC TV18, the stock has declined by ₹251 from its peak but remains above its 52-week low of ₹1,165.70 touched on April 2, 2026. At Tuesday's closing price, Cipla had a market capitalisation of ₹1,14,876.72 crore. According to Bloomberg analyst data cited by CNBC TV18, 26 of the 41 analysts covering Cipla recommend 'Buy', while nine have a 'Hold' rating and six recommend 'Sell'. The stock has fallen nearly 6% so far this year and more than 10% over the last 12 months. Despite Cipla's decline, the broader pharmaceutical sector showed strength with the Nifty Pharma index rising 224.70 points to 26,564, gaining 17.37% so far this year.
